Prognostic Significance of Survivin Expression in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP Therapy: A Report from the International DLBCL Rituximab-CHOP Consortium Program
Publication
, Conference
Liu, Z; Xu-Monette, ZY; Cao, X; Visco, C; Tzankov, A; Montes-Moreno, S; Dybkær, K; Chiu, A; Orazi, A; Zu, Y; Bhagat, G; Richards, KL; Hsi, ED ...
Published in: Clinical Lymphoma Myeloma and Leukemia
June 2015
Duke Scholars
Published In
Clinical Lymphoma Myeloma and Leukemia
DOI
ISSN
2152-2650
Publication Date
June 2015
Volume
15
Start / End Page
S216 / S216
Publisher
Elsevier BV
Related Subject Headings
- 3211 Oncology and carcinogenesis
- 3201 Cardiovascular medicine and haematology
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Liu, Z., Xu-Monette, Z. Y., Cao, X., Visco, C., Tzankov, A., Montes-Moreno, S., … Young, K. H. (2015). Prognostic Significance of Survivin Expression in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP Therapy: A Report from the International DLBCL Rituximab-CHOP Consortium Program. In Clinical Lymphoma Myeloma and Leukemia (Vol. 15, pp. S216–S216). Elsevier BV. https://doi.org/10.1016/j.clml.2015.04.087
Liu, Zhiyu, Zijun Y. Xu-Monette, Xin Cao, Carlo Visco, Alexander Tzankov, Santiago Montes-Moreno, Karen Dybkær, et al. “Prognostic Significance of Survivin Expression in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP Therapy: A Report from the International DLBCL Rituximab-CHOP Consortium Program.” In Clinical Lymphoma Myeloma and Leukemia, 15:S216–S216. Elsevier BV, 2015. https://doi.org/10.1016/j.clml.2015.04.087.
Liu Z, Xu-Monette ZY, Cao X, Visco C, Tzankov A, Montes-Moreno S, et al. Prognostic Significance of Survivin Expression in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP Therapy: A Report from the International DLBCL Rituximab-CHOP Consortium Program. In: Clinical Lymphoma Myeloma and Leukemia. Elsevier BV; 2015. p. S216–S216.
Liu, Zhiyu, et al. “Prognostic Significance of Survivin Expression in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP Therapy: A Report from the International DLBCL Rituximab-CHOP Consortium Program.” Clinical Lymphoma Myeloma and Leukemia, vol. 15, Elsevier BV, 2015, pp. S216–S216. Crossref, doi:10.1016/j.clml.2015.04.087.
Liu Z, Xu-Monette ZY, Cao X, Visco C, Tzankov A, Montes-Moreno S, Dybkær K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WWL, Han van Krieken J, Huh J, Ai W, Ponzoni M, Ferreri AJM, Farnen JP, Møller MB, Winter JN, Piris MA, Medeiros LJ, Young KH. Prognostic Significance of Survivin Expression in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP Therapy: A Report from the International DLBCL Rituximab-CHOP Consortium Program. Clinical Lymphoma Myeloma and Leukemia. Elsevier BV; 2015. p. S216–S216.
Published In
Clinical Lymphoma Myeloma and Leukemia
DOI
ISSN
2152-2650
Publication Date
June 2015
Volume
15
Start / End Page
S216 / S216
Publisher
Elsevier BV
Related Subject Headings
- 3211 Oncology and carcinogenesis
- 3201 Cardiovascular medicine and haematology
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences